Cargando…

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib

INTRODUCTION/OBJECTIVES: The objective of this study is to describe the treatment patterns and use of healthcare resources in a cohort of Colombian patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) or tofacitinib. METHOD: This is a descri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machado-Alba, Jorge Enrique, Machado-Duque, Manuel E., Gaviria-Mendoza, Andres, Reyes, Juan Manuel, Gamboa, Natalia Castaño
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943490/ https://www.ncbi.nlm.nih.gov/pubmed/32997316 http://dx.doi.org/10.1007/s10067-020-05432-6

Ejemplares similares

Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia
por: Machado-Duque, Manuel E, et al.
Publicado: (2023)

Evaluation of Treatment Patterns and Direct Costs Associated with the Management of Neuropathic Pain
por: Machado-Duque, Manuel E, et al.
Publicado: (2020)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Incidence and factors related to SARS-CoV-2 infection in a cohort of patients with rheumatoid arthritis from a health service provider in Colombia during the COVID-19 pandemic
por: Valladales-Restrepo, Luis Fernando, et al.
Publicado: (2022)

Lipid-lowering drug prescriptions in a group of Colombian patients
por: Gaviria-Mendoza, Andrés, et al.
Publicado: (2019)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Real-World Evidence: Pharmacoepidemiology for Daily Clinical Practice—An Experience from Colombia
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
por: Strand, Vibeke, et al.
Publicado: (2015)

Patterns of Antibiotic Prescription in Colombia: Are There Differences between Capital Cities and Municipalities?
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2023)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety
por: Bird, Paul, et al.
Publicado: (2019)

Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database
por: Machado‐Alba, Jorge E., et al.
Publicado: (2020)

Use of Tramadol or Other Analgesics in Patients Treated in the Emergency Department as a Risk Factor for Opioid Use
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia
por: Gaviria-Mendoza, Andrés, et al.
Publicado: (2022)

The frequency of complications in a cohort of patients diagnosed with hemophilia A and hemophilia B receiving prophylactic treatment in Colombia: A retrospective noninterventional study
por: Machado Alba, Jorge E., et al.
Publicado: (2023)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2018)

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
por: Song, Gwan Gyu, et al.
Publicado: (2014)

Trends in Opioid Use in a Cohort of Patients with Rheumatoid Arthritis
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Trends in the Use of Sedative-Hypnotics, Opioids, and Neuromuscular Blockers in Hospitalized Patients During the COVID-19 Pandemic: Observational Retrospective Study
por: Machado-Duque, Manuel E., et al.
Publicado: (2022)

Patterns and Trends in the Use of Medications for COPD Control in a Cohort of 9476 Colombian Patients, 2017–2019
por: Machado-Duque, Manuel Enrique, et al.
Publicado: (2023)

Factors Associated with Survival in Patients Undergoing Invasive Mechanical Ventilation in an Intensive Care Unit in Colombia, 2017–2018: A Retrospective Cohort Study
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2021)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2014)

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
por: Li, Zhanguo, et al.
Publicado: (2018)

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
por: Strand, Vibeke, et al.
Publicado: (2017)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Utilization Patterns and Trends in the Use of Medications for Asthma in a Cohort of Colombian Patients
por: Machado-Duque, Manuel Enrique, et al.
Publicado: (2022)

Clinical Experience with Oral Tofacitinib in a Patient with Alopecia Areata Universalis and Rheumatoid Arthritis
por: Abe, Daniele Tiemi, et al.
Publicado: (2020)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018
por: Machado-Duque, Manuel E., et al.
Publicado: (2021)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia
por: Machado-Duque, Manuel E., et al.
Publicado: (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6i2f68atminlq5urrcssn3eqsr